Elevated circulating levels of interleukin-18 are closely associated with the metabolic syndrome, predict cardiovascular events and mortality, and precede the development of type 2 diabetes.
The metabolic syndrome is thought to be associated with a chronic low-grade inflammation, and a growing body of evidence suggests that interleukin-18 (IL-18) might be closely related to the metabolic syndrome and its consequences. Circulating levels of IL-18 have been reported to be elevated in subjects with the metabolic syndrome, to be closely associated with the components of the syndrome, to predict cardiovascular events and mortality in populations with the metabolic syndrome and to precede the development of type 2 diabetes. IL-18 is found in the unstable atherosclerotic plaque, in adipose tissue and in muscle tissue, and is subject to several regulatory steps including cleavage by caspase-1, inactivation by IL-18 binding protein and the influence of other cytokines in modulating its interaction with the IL-18 receptor. The purpose of this review is to outline the role of IL-18 in the metabolic syndrome, with particular emphasis on cardiovascular risk and the potential effect of life style interventions.
Trøseid et al. (Fri,) conducted a review in Metabolic syndrome. Interleukin-18 (IL-18) was evaluated. Elevated circulating levels of interleukin-18 are closely associated with the metabolic syndrome, predict cardiovascular events and mortality, and precede the development of type 2 diabetes.